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Corn, one of the most important forage crops worldwide, 
has  proven  to  be a  useful  expression  vehicle  due  to  the 
availability of established transformation procedures for 
this well-studied plant. The exotoxin Apx, a major virulence 
factor, is recognized as a common antigen of Actinobacillus 
(A.)  pleuropneumoniae,  the  causative  agent  of  porcine 
pleuropneumonia.  In  this  study,  a  cholera  toxin  B 
(CTB)-ApxIIA#5  fusion  protein  and  full-size  ApxIIA 
expressed in corn seed, as a subunit vaccine candidate, were 
observed to induce Apx-specific immune responses in mice. 
These results suggest that transgenic corn-derived ApxIIA 
and  CTB-ApxIIA#5  proteins  are  potential  vaccine 
candidates against A. pleuropneumoniae infection.
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Transgenic plants have been used for the production and 
delivery of edible oral subunit vaccines [3,10]. Plant-based 
vaccines possess some advantages over other types of 
vaccine biotechnology such as increased safety, 
anticipated low cost of mass vaccination programs, and 
wider use of vaccines for veterinary medicine [9,10]. 
Several plant-derived vaccine candidates have been 
developed, and their immunogenicity and ability to protect 
against microbial infection were evaluated [3]. Corn, a 
major forage crop, is a particularly attractive expression 
vehicle due to its extensively studied genetics and 
amenability to established transformation procedures [7]. 
In addition, grain seeds provide excellent systems for oral 
delivery of subunit vaccines because of their low water 
content and long shelf-life [7].
Actinobacillus (A.) pleuropneumoniae is the etiological 
agent of severe hemorrhagic, necrotizing pneumonia often 
associated with fibrinous pleuritis in pigs, and is 
responsible for significant economic losses worldwide [2]. 
Among several virulence factors such as exotoxins, 
lipopolysaccharides, capsular polysaccharide, membrane 
proteins, and adhesion factors, the Apx exotoxin is 
believed to be correlated with A. pleuropneumoniae 
virulence [2]. Apx toxins are highly immunogenic and 
induce a substantial production of antibodies during A. 
pleuropneumoniae infection [4]. ApxII is expressed by all 
but serotype 10, while ApxI and ApxIII are expressed by 
different serotypes in various combinations [2]. In 
addition, serovars producing ApxI and ApxII are the most 
virulent. Therefore, ApxII could effectively serve as an 
antigen for vaccines against A. pleuropneumoniae. 
ApxIIA, which is expressed in Saccharomyces cerevisiae 
and transgenic tobacco, has previously been reported to be 
capable of inducing protective immune responses against 
A. pleuropneumoniae in mice [6,8,12]. The neutralizing 
epitope of ApxIIA (ApxIIA#5) from A. pleuropneumoniae 
serotype 2 was isolated in Korea and found to induce a 
protective immune response against A. pleuropneumoniae. 
Smaller fragments of this epitope are easily expressed in 
large quantities using a heterologous expression system 
[11].
Cholera toxin B (CTB) binds to GM1-ganglioside at the 
surface of mammalian intestinal epithelial cells, including 
the M cells of gut-associated lymphoid tissue [1]. The CTB 
subunit protein has also been found to induce mucosal 
immunity as an effective carrier molecule [1]. Therefore, it 
was chosen as a fusion protein for the present study.
The generation of transgenic corn expressing CTB- 
ApxIIA#5 fusion protein (0.93 kb) and full-size (2.8 kb) 
ApxIIA has been previously described [5]. One gram of the 
corns expressing the CTB-ApxIIA#5 fusion protein or 
full-size ApxIIA was ground in liquid nitrogen using a 402    Min-Kyoung Shin et al.
Fig. 1. ApxII-specific IgG (A) and IgA (B) levels 2 weeks after 
final boosting (**p < 0.01). CTB: cholera toxin B.
Fig. 2. ApxII-specific memory B cells producing IgG (A) and 
IgA (B) in mice immunized with corn-derived ApxIIA (■: 
untreated control, ■: ApxIIA, □: lipopolysaccharides; *p < 
0.05, **p < 0.01).
mortar and pestle. Soluble proteins were extracted at a 
solid-to-liquid ratio of 1 : 10 with phosphate buffered 
saline (PBS). The extracted protein was subcutaneously 
injected into mice to evaluate the immunogenicity of the 
transgenic corn-derived ApxIIA and CTB-ApxIIA#5 
fusion proteins. Four-week-old ICR female mice (Orient 
Bio, Korea) were used through this study following policy 
and regulation for the care and use of laboratory animal 
(Laboratory Animal Center, Seoul National University, 
Korea). The mice were divided into three groups: a 
non-vaccinated control group and groups that received 
injections of the CTB-ApxIIA#5 fusion protein or full-size 
ApxIIA. Four mice in each group were boosted 
subcutaneously with 200 μL of soluble antigen extracts 
mixed with complete Freund’s adjuvant (Sigma, USA), 
and were injected twice with the same antigen mixed with 
incomplete Freund’s adjuvant (Sigma, USA).
Blood samples and spleens were collected 2 weeks after 
the final immunization. A spleen cell suspension was 
prepared by gently pressing and straining the spleen tissue 
through a 100-μm pore nylon cell strainer (100 μm; BD 
Falcon, USA) with a plunger. A 5 × 10
6 cells/mL 
suspension was cultured for 5 days in RPMI-1640 medium 
(Gibco-BRL, USA) supplemented with 10% fetal bovine 
serum (Gibco-BRL, USA) at 37
oC in 5% CO2. Spleen cells 
of each group were stimulated with the recombinant 
ApxIIA (2 μg/mL), and Concanavalin A (ConA, 2 μg/mL) 
to evaluate production of interferon (IFN)-γ, interleukin 
(IL)-4, and nitric oxide (NO).
After stimulation, the secreted concentration of IFN-γ and 
IL-4 was measured using the enzyme-linked immunosorbent 
assay (ELISA) kit (eBioscience, USA) according to the 
manufacturer’s instructions. The levels of NO derived 
from the culture supernatant were determined by the Griess 
method [13]. ApxIIA-specific IgG and IgA-memory B cell 
enzyme-linked immunospot (ELISPOT) assays were 
performed using mouse IgG and IgA ELISPOT kits 
(Mabtech, USA) according to the manufacture’s instruction.
The level of antigen-specific antibody in serum was 
determined with an ELISA. For this, 96-well microplates 
were coated with 1 μg/mL of the recombinant ApxIIA 
antigen and incubated overnight at 4
oC. The plates were 
then blocked with 1% bovine serum albumin (Sigma, 
USA) in a solution of PBS containing 0.1% Triton X-100 
(PBST) for 2 h at 37
oC. After washing with PBST, 1 : 20 
diluted mice sera were added to each well and incubated for 
1 h at 37
oC. Goat anti-mouse IgG (H + L)-HRP conjugate 
(Bio-Rad, USA) or anti-mouse IgA (α-chain specific)- 
HRP conjugate (Bethyl, USA) was used at 1 : 2,000 as a 
secondary antibody, and 2,2´-azin-bis (3-ethylbenzthiazoline- 
6-sulfonic acid) substrate (Bio-Rad, USA) was added to 
develop the color. Optical density was measured at 405 nm 
using an Emax Precision microplate reader (Molecular 
Devices, USA). Statistical significance was analyzed with 
Student’s  t-test using SPSS (ver 17.0; SPSS, USA). 
Differences were considered significant if a p-value < 0.05 
was obtained.
The level of ApxIIA-specific IgG antibodies significantly 
increased in serum from the mice boosted with the 
CTB-ApxIIA#5 fusion protein and full-size ApxIIA from 
the transgenic corn compared to the control mice at the 
time of the final booster shots (p < 0.01). However, there 
were no significant differences in the anti-ApxIIA IgA 
antibody responses between the injected groups and the 
control group (Fig. 1). The production of ApxIIA-specific 
IgG memory B cells was observed in spleens from the mice 
boosted with the CTB-ApxIIA#5 fusion protein and 
full-size-ApxIIA by ELISpot (p < 0.01) from the 
transgenic corn (Fig. 2). In addition, ApxIIA-specific IgA 
memory B cells were produced in the mice injected with 
the CTB-ApxIIA#5 fusion protein (p < 0.05; Fig. 2).
The secretion of IFN-γ, IL-4, and NO from spleen cells 
was measured as an indicator of immune response 
induction. After in vitro stimulation, spleen cells from the 
group injected with full-size ApxIIA produced high levels 
of IFN-γ, a T helper type 1 cytokine (p < 0.05; Fig. 3), while 
the production of IL-4, a T helper type 2 (Th2) cytokine, 
was not detected in any group (data not shown). The 
transgenic corn-derived ApxIIA, particularly the CTB- Transgenic corn-derived ApxIIA fused with CTB    403
Fig. 3. Secretion of interferon-γ (A) and nitric oxide (B) from 
murine splenocytes stimulated with ApxIIA and ConA, or the 
untreated control (■: administration of cholera toxin B- 
ApxIIA#5, □: administration of full ApxIIA; *p < 0.05, **p < 0.01).
ApxIIA#5 fusion protein, was found to induce the 
production of antigen-specific antibodies (Figs. 1 and 2), 
although IL-4 related to a Th2 immune response was not 
detected. In addition, high NO production was detected in 
the mice treated with the CTB-ApxIIA#5 fusion protein 
and full-size ApxIIA after in vitro stimulation (p < 0.01; 
Fig. 3).
Based on the induced antigen-specific immune responses, 
we concluded that the transgenic corn-derived CTB- 
ApxIIA#5 fusion protein and full-size ApxIIA are capable 
of effectively inducing Apx-specific immune responses in 
mice. In particular, the group injected with the CTB- 
ApxIIA#5 fusion protein showed higher ApxIIA-specific 
antibody titers than the group injected with the full-size 
ApxIIA. Fusing the ApxIIA#5 antigenic fragment with the 
CTB protein could be thought to improve the efficiency of 
antigen delivery to the host immune system based on these 
results. Moreover, the small size of the ApxIIA epitope 
contributes to increased expression levels in a heterologous 
expression system [11]. Consequently, the transgenic corn 
expressing the CTB-ApxIIA#5 fusion protein and full-size 
ApxIIA is a promising candidate for an effective vaccine 
against A. pleuropneumoniae. We are currently preparing 
for further experiments to develop a transgenic corn- 
derived oral vaccine against A. pleuropneumoniae based 
on the results of the present study.
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